Read participant evidence without turning it into a promise
Participant studies can reveal questions that a registry entry does not answer. They cannot tell you how a different protocol, site, condition, or person will experience participation. Read the population, setting, method, and limits before applying a finding.
| Evidence | Who contributed | What it can reveal | Important limit |
|---|---|---|---|
| Qualitative synthesis of trial burden | 45 studies involving 1,732 adult randomized-trial participants | Patterns of psychological, physical, and financial burden across the trial timeline | The included studies differed in condition, intervention, country, and method |
| Questionnaire interview study | 20 participants from one chronic-neck-pain trial | How people understood and answered repeated outcome questions | A small, all-female older sample from one trial |
| Results-return interview study | 38 women from a pregnancy trial | How later findings can change the meaning participants give to consent | A specific and emotionally consequential long-term follow-up context |
| U.S. post-trial focus groups | 93 current or recent participants in 10 groups | Expectations for information, transition care, and access after participation | Views and ethical expectations, not a statement of legal entitlement |
Qualitative evidence describes how and why an experience can occur. It does not establish how frequently it occurs. Large surveys add scale but can cover many kinds of research and may not explain why respondents answered as they did.
Inspect burden across the entire participation timeline
A systematic thematic synthesis (opens in a new tab) found reports of psychological, physical, and financial burden from consent and randomization through follow-up and study closure. The same synthesis also identified benefits reported by participants, including feeling useful, gaining a sense of control, and receiving attention from a research team.
Use both sides of that evidence. Ask what could feel worthwhile and what could become difficult. Map screening, uncertainty about assignment, procedure recovery, travel, home tasks, expenses, repeated measurements, and the transition after the final activity. Do not reduce burden to visit count.
Test the assumptions that trust can hide
Trust in a clinician, institution, or research team can support a difficult decision. It can also carry assumptions that the consent document never confirms. A qualitative genomic-research study (opens in a new tab) and the results-return interview study (opens in a new tab) found that expectations about benefit, safety, or return of information were shaped by existing clinical relationships or by the meaning participants assigned to the research.
Write the assumptions down. Could you receive the experimental intervention? Is personal benefit expected, possible, or absent? Which findings will be returned? Who makes that decision? What happens if the aggregate result is disappointing or identifies a concern years later? Ask the study team to separate what the protocol promises from what everyone hopes the research will accomplish.
OHRP describes informed consent (opens in a new tab) as an ongoing process. Revisit the decision when new risk information, procedures, vendors, or follow-up requests appear.
Treat questionnaires and diaries as study procedures
Questionnaires can prompt reflection, force a choice between imperfect answers, repeat sensitive subjects, or become difficult when symptoms fluctuate. A qualitative study nested in a randomized trial (opens in a new tab) showed that participants used different strategies to interpret and complete standardized instruments.
Before enrollment, ask to see a sample when the study can provide one. Record the number of items, recall period, completion window, frequency, language, accessibility, correction rule, and estimated time. Ask whether a caregiver may help, whether help changes who should answer, and how technical failures are recorded. During participation, report uncertainty or a missed entry. Do not invent an answer to appear compliant.
Audit the burden that remote participation moves into the home
Remote visits can reduce travel. They can also add device setup, charging, shipping, connectivity, identity checks, app permissions, home access, and support calls. In a study of 48 decentralized-trial stakeholders (opens in a new tab), burden and trust remained central to recruitment and retention. Only two interviewees were patient representatives, so read the findings as a stakeholder view rather than a participant prevalence estimate.
Complete one rehearsal before relying on the remote process. Test the device, captioning or assistive technology, login recovery, data connection, support line, sample packaging, and backup method. Confirm which tasks can move and which remain fixed. Ask who sees information from each app, courier, home-health service, laboratory, and device vendor.
Plan for the emotional and practical work of study closeout
The final participant visit may occur before database analysis, registry results, unblinding, or publication. The EPIC focus-group study (opens in a new tab) found that U.S. participants expressed expectations about treatment information, trial findings, transition care, and access after participation. Those views do not create a universal entitlement. They identify matters to settle before enrollment.
Ask when the intervention ends, how regular care resumes, whether assignment will be disclosed, how late safety information reaches you, and how to find aggregate results. The results-return study (opens in a new tab) also shows that receiving later findings can change how some participants understand an earlier decision. Ask what support accompanies unexpected or sensitive information.
Keep the NCT or other registry identifier. ClinicalTrials.gov explains how to read posted results (opens in a new tab); a registry result record and a journal article serve different purposes and may appear on different schedules.
Learn from positive experience without using it as a forecast
Participant experience is not defined only by problems. In the 2023/24 NIHR participant survey (opens in a new tab), 35,519 adults, children, and young people responded across health and social-care research. Ninety-one percent of adult respondents said they would consider taking part again; 92 percent felt their contribution was valued; and 95 percent felt treated with kindness and respect.
The survey covers a broader research system than U.S. clinical trials, and self-selected survey responses do not predict an individual experience. Its measures still identify concrete standards to ask about: clear information, respectful treatment, the ability to raise concerns, and recognition of the participant’s contribution.
Convert published experience into eight direct questions
- Which part of participation has created the most work for people in this protocol?
- What assumptions about assignment, benefit, or results should I correct now?
- How much time do diaries, questionnaires, devices, and support take on a difficult week?
- Which visit or task windows cannot move?
- What happens after a missed task, technology failure, hospitalization, or schedule disruption?
- How can I raise a concern without routing it through the person who recruited me?
- What changes at my final participant activity, and what remains open afterward?
- How will I learn my assignment, individual findings, aggregate results, and late safety information when applicable?
Sources for this guide
Official guidance controls regulatory claims. Peer-reviewed research is identified when participant experience requires evidence beyond agency guidance. Links were checked September 5, 2026.
- Naidoo et al., BMC Medicine. The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence (opens in a new tab).
- Holmberg et al., BMJ Open. Clinical trial participants’ experiences of completing questionnaires: a qualitative study (opens in a new tab).
- Tarrant et al., Health Expectations. Consent revisited: the impact of return of results on participants’ views and expectations about trial participation (opens in a new tab).
- Berrios et al., Journal of Genetic Counseling. Enrolling Genomics Research Participants through a Clinical Setting: the Impact of Existing Clinical Relationships on Informed Consent and Expectations for Return of Research Results (opens in a new tab).
- Sofaer et al., Journal of Medical Ethics. Subjects’ views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study (opens in a new tab).
- Coyle et al., Trials. A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs) (opens in a new tab).
- National Institute for Health and Care Research. Participant in Research Experience Survey 2023/24 (opens in a new tab).
- Office for Human Research Protections. Informed Consent FAQs (opens in a new tab).
- ClinicalTrials.gov. How to Read Study Results (opens in a new tab).